Home
Resources
Publications
Acetylation Site Specificities of Lysine Deacetylase Inhibitors in Human Cells

Acetylation Site Specificities of Lysine Deacetylase Inhibitors in Human Cells

Christian Schölz, Brian T Weinert, Sebastian A Wagner, Petra Beli, Yasuyuki Miyake, Jun Qi, Lars J Jensen, Werner Streicher, Anna R McCarthy, Nicholas J Westwood, Sonia Lain, Jürgen Cox, Patrick Matthias, etc.

Nat Biotechnol. 2015 Apr;33(4):415-23.

PMID: 25751058

Abstract:

Lysine deacetylases inhibitors (KDACIs) are used in basic research, and many are being investigated in clinical trials for treatment of cancer and other diseases. However, their specificities in cells are incompletely characterized. Here we used quantitative mass spectrometry (MS) to obtain acetylation signatures for 19 different KDACIs, covering all 18 human lysine deacetylases. Most KDACIs increased acetylation of a small, specific subset of the acetylome, including sites on histones and other chromatin-associated proteins. Inhibitor treatment combined with genetic deletion showed that the effects of the pan-sirtuin inhibitor nicotinamide are primarily mediated by SIRT1 inhibition. Furthermore, we confirmed that the effects of tubacin and bufexamac on cytoplasmic proteins result from inhibition of HDAC6. Bufexamac also triggered an HDAC6-independent, hypoxia-like response by stabilizing HIF1-α, providing a possible mechanistic explanation of its adverse, pro-inflammatory effects. Our results offer a systems view of KDACI specificities, providing a framework for studying function of acetylation and deacetylases.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP537049404	Tubacin		537049-40-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: